Molnupiravir influenza experimental training had surprising results
A new antiviral drug, called MK-4482 / EIDD-2801 or molnupiravir, manages to completely stop coronavirus transmission within 24 hours, according to research by the Institute of Biomedicine at the University of Georgia. It is an experimental anti-influenza drug that has only recently been developed, but is shown to have a “side effect” and is a contraindication against COVID-19.
“This is the first demonstration of an oral drug that quickly blocks SARS-CoV-2 transmission and can change the rules of the game,” the researchers say in a paper published in the journal Nature Microbiology.
Preventing mass transmission of the virus is key to controlling COVID-19 and mitigating the catastrophic effects of the pandemic. However, because molnupiravir is taken orally, treatment can be started early, which facilitates its effectiveness in three ways: eliminating the development of the infection into severe stages; shortening the infection phase and consequently reducing the emotional and economic consequences of long-term isolation of the patient; quick removal of local occurrences.
“We have previously seen that MK-4482 / EIDD-2801 has a wide range of anti-respiratory RNA viral activities, and that oral treatment of infected animals with the drug reduces the number of viruses spread in various measures, greatly reducing their transmission. COVID-19 is a strong candidate for pharmacological control, ”the researchers wrote.
Molnupiravir has been used in ferrets because they believe that these small predators are a suitable model for research “because they spread SARS-CoV-2 easily, but many of them do not develop a serious disease very similar to SARS-CoV-2 spread.” CoV-2 in young people “.
According to Joseph Wolfer of Plemper Laboratory and one of the authors of the study, the process was as follows: the group infected ferrets with coronavirus and treated them with molnupiravir. During treatment, infected ferrets were released into healthy animals and no cases of infection were reported. At the same time, placebo-treated ferrets were rapidly developed and cured.